Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) is widely used for reducing pain originating from upper abdominal organs. It is mainly indicated to treat pancreatic cancer pain, but also to relieve pain as a result of chronic pancreatitis. Real-time guidance and color Doppler imaging by EUS made the procedure easier and safer, resulting in greater pain relief. Currently, two techniques are used for EUS-CPN. The classic approach, known as the central technique, involves injection of a neurolytic agent at the base of the celiac axis. In the bilateral technique, the neurolytic agent is injected on both sides of the celiac axis. In addition, EUS-guided direct celiac ganglia neurolysis (EUS-CGN) was introduced recently. Pain relief is achieved by EUS-CPN in 70-80% of patients with pancreatic cancer and in 50-60% of those with chronic pancreatitis. The bilateral technique may be more efficient than the central technique, although the central technique is easier and possibly safer. Moreover, EUS-CGN may provide greater pain relief than conventional EUS-CPN. Procedure-related complications include transient pain exacerbation, transient hypotension, transient diarrhea, and inebriation. Although most complications are not serious, major adverse events such as retroperitoneal bleeding, abscess, and ischemic complications occasionally occur.
INTRODUCTION

C ELIAC PLEXUS NEUROLYSIS (CPN), a technique of chemical ablation of the celiac plexus nerves, was initially reported in 1914
1 and done as an intraoperative procedure. Subsequently, it has been carried out under radiographic, fluoroscopic, computed tomography (CT), or ultrasonographic imaging guidance. Endoscopic ultrasoundguided CPN (EUS-CPN) was introduced by Faigel et al. 2 and Wiersema and Wiersema 3 in 1996. This technique seems to be safer, more accurate, and more convenient than previous approaches because it can be carried out under the guidance of real-time precise imaging. In addition, the assessment with color Doppler ultrasonography allows avoiding injury of the interposing vessels. Indeed, a randomized controlled trial (RCT) showed that the EUSguided approach provided more persistent pain relief than the CT-guided approach. 4 EUS-CPN combined with standard analgesic treatments is suggested to be superior to the analgesic treatment alone in reducing pain. 5 Therefore, EUS-CPN is now widely practiced, and various EUS approaches have been developed in order to improve the efficacy of this technique. 6, 7 We herein review the technical variations, effectiveness, and adverse events of this procedure.
METHODS
T HE MEDLINE/PUBMED and Cochrane Library electronic databases were searched for manuscripts in English published between December 1996 and September 2016 using the keywords 'EUS OR endoscopic ultrasound' AND 'block OR neurolysis'. The search identified 63 articles. Fifty-four articles were deemed relevant to this review based on title screening. After evaluation of abstracts, complete texts were obtained for potentially relevant articles. A manual recursive search of the reference sections of these articles was carried out to identify other potentially relevant articles. These papers were then reviewed in detail.
PRINCIPLES OF CELIAC PLEXUS BLOCK AND NEUROLYSIS
T HE CELIAC PLEXUS is located around the origins of the celiac axis (CA) and the superior mesenteric artery (SMA). It contains several ganglia and the interconnecting neural rami. The plexus is responsible for transmitting pain sensations originating from the upper abdominal organs, including the pancreas, liver, gallbladder, stomach, and ascending and transverse colons. CPN is the technique in which a neurolytic or analgesic agent injected into the celiac plexus disrupts the transmission of pain signals from afferent nerves to the spinal cord. Ethanol is generally used as a neurolytic agent, and bupivacaine is mainly used as an analgesic agent. Instead of ethanol, a local analgesic agent and a steroid are often used for pain originating from benign diseases. 8 This procedure, which is distinct from EUS-CPN, is sometimes called EUS-guided celiac plexus block (EUS-CPB).
INDICATIONS
A S MENTIONED ABOVE, the theoretical indications of celiac plexus neurolysis and block is pain originating from the upper abdominal organs. In particular, the most significant indication of EUS-CPN is pancreatic cancer pain because pain is a common symptom reported by 90% of patients with advanced pancreatic cancer, and it represents a major issue in the management of patients. 9 The current management of cancer pain follows the World Health Organization (WHO) three-step ladder for pain control, starting with non-opioid analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and progressing to increasing doses of opioid analgesics. 10 However, opioids often provide incomplete pain relief and their dose is limited by frequent adverse effects such as nausea, constipation, somnolence, confusion, dependence, and addiction. 11, 12 In such cases, CPN can be an additional option, which may reduce the risk of opioid-induced adverse effects. Furthermore, a recent study suggested that early EUS-CPN provides better pain relief and greater reduction in morphine consumption than conventional pain management. 13 This may indicate that EUS-CPN can be used at earlier stages of pain management than is currently accepted. In addition, as previously mentioned, EUS-CPN is also used to alleviate pain originating from benign diseases such as chronic pancreatitis.
TECHNIQUES OF EUS-CPN
T WO APPROACHES ARE currently used when carrying out EUS-CPN. The classic approach, known as the central technique, involves injection of the agent at the base of the CA. In the second approach, the bilateral technique, the neurolytic agent is injected on both sides of the CA (Fig. 1) . Absolute ethanol is the usual neurolytic agent in the EUS-CPN, although phenol can also be used. In addition, 0.25-0.75% (mainly 0.25%) bupivacaine is typically given before the neurolytic agent. However, anesthetic agents such as bupivacaine with anti-inflammatory agents such as triamcinolone and depo-medrol are often injected instead of a neurolytic agent for pain as a result of chronic pancreatitis. 8, 14, 15 Central technique
In the central technique, the abdominal aorta is initially visualized in the longitudinal plane on the EUS image through the posterior wall of the upper gastric body. The aorta is then traced to identify the CA. Subsequently, a needle is pierced and advanced to a point just above the point where the CA originates from the aorta (Fig. 2) . The agent is injected into the region until the echogenic cloud is sufficiently widespread. A total amount of ethanol is usually 10-20 mL in the EUS-CPN.
Bilateral technique
After the origin of the CA is identified, the echoendoscope is rotated clockwise until the CA and SMA are no longer visible. The needle is then advanced to the left alongside the Figure 1 Two approaches for endoscopic ultrasoundguided celiac plexus neurolysis (EUS-CPN). In the central approach, a neurolytic agent is injected at the base of the celiac axis (red arrow). In the bilateral approach, the neurolytic agent is injected on both sides of the celiac axis (blue arrows).
CA and SMA, up to a position lateral to the point where the SMA originates from the aorta. The agent is injected into this region. Next, the needle is withdrawn, and the echoendoscope is rotated counterclockwise until the CA and SMA are no longer visible. The needle is advanced to the right lateral base of the SMA, and the agent is injected once again. The total amount of ethanol is the same as for the central technique.
EUS-guided direct celiac ganglia neurolysis
In EUS-guided direct celiac ganglia neurolysis (EUS-CGN) developed by Levy et al. 16 in 2008, the celiac ganglion (CG) is identified, and punctured with a needle, followed by absolute ethanol injection. The CG are usually identified between the aorta and the left adrenal gland in most cases and also cephalad to the origin of the CA in some cases. These CG are hypoechoic and often exhibit hypoechoic connections, which probably represent the adjoining neural rami. They can be caterpillar-like (Fig. 3) or small and nodular. 17 Absolute ethanol is injected until the targeted ganglion becomes hyperechoic and difficult to visualize (Fig. 4) .
EFFICACY OF EUS-CPN AND -CPB
P REVIOUS STUDIES DEMONSTRATED relatively good results with respect to pain relief. 3, 4, 8, In an initial evaluation by Wiersema and Wiersema, 3 79-88% of patients experienced long-lasting improvement in pain scores, whereas 82-91% of patients required the same or a lower amount of pain medication. Two meta-analyses have been published. Puli et al. 8 extracted data from eight studies (N = 283) of EUS-CPN for pain as a result of pancreatic cancer and nine studies of EUS-CPB for pain as a result of chronic pancreatitis (N = 376). The pooled proportion of patients with relief of pain as a result of pancreatic cancer was 80.12% (95% CI = 74. 44-85.22) and that of patients with relief of pain as a result of chronic pancreatitis was 59.45% (95% CI = 54.51-64.30). In the analysis by Kaufman et al.
11
, six relevant studies including a total of 221 patients were identified for chronic pancreatitis and five relevant studies with a total of 119 patients for pancreatic cancer. EUS-CPN was effective in alleviating pain in 72.54% of patients with pancreatic cancer and in 51.46% of patients with chronic pancreatitis.
Central technique versus bilateral technique
Puli et al. 8 compared the bilateral and unilateral techniques in terms of treatment efficacy. The rate of pain relief was much higher in pancreatic cancer patients treated with the bilateral procedure (84.54%; 95% CI = 72.15-93.77) than in those treated by the central procedure (45.99%; 95% CI = 37.33-54.78). Sahai et al. 24 assessed the short-term safety and efficacy of central and bilateral EUS-CPN/EUS-CPB in 160 patients (71 treated centrally, 89 treated bilaterally). The mean pain reduction score was 70.4% in patients treated bilaterally compared to 45.9% in those treated centrally (P = 0.0016). A positive response (>50% reduction in pain score) was also significantly more frequent in the bilaterally treated group (77.5 vs 50.7%, P = 0.0005). The only predictor of a positive response was the use of the bilateral procedure (odds ratio = 3.55; 95% CI = 1.72-7.34). These results suggested that the bilateral procedure is more effective than the central procedure. However, a subsequent RCT found no difference in pain relief between the central and bilateral techniques (central: 69% vs bilateral: 81%; P = 0.340). 28 In addition, a retrospective study also showed similar pain reduction in the central and bilateral procedures. 31 It is still a matter of debate whether the bilateral approach is superior to the central approach in terms of pain relief.
Broad distribution of the neurolytic agent
A multivariate analysis by Iwata et al. 27 revealed that direct invasion of the celiac plexus and distribution of ethanol only on the left side of the CA (to both sides of the CA) were significant predictive factors of a negative response to EUS-CPN (odds ratios = 4.82 and 8.67, P = 0.0387 and 0.0224). Sakamoto et al. 26 also emphasized the importance of a broad distribution of the neurolytic agent. In their retrospective study, ethanol was distributed more widely and better pain relief was obtained with a new technique, EUSguided broad plexus neurolysis (EUS-BPN), in which the neurolytic agent is distributed over the SMA using a thin 25-gauge needle, than in standard EUS-CPN. These results suggested that broad distribution of the injected ethanol was an important factor predicting a good response to EUS-CPN. In contrast, the volume of the injected ethanol does not appear to be associated with better results. In this regard, LeBlanc et al. 30 found no differences in complications and the extent of pain relief between EUS-CPN with 10 and 20 mL of ethanol.
CPN vs CGN
EUS-CGN may be safer and more efficient than EUS-CPN because it allows for the precise delivery of neurolytic agents into an individual celiac ganglion. The initial report on EUS-CGN by Levy et al. 16 showed a surprisingly high efficiency rate, although the study used a small sample size. Pain relief was achieved in 16 of 17 (94%) pancreatic cancer patients treated by EUS-CGN. In the case of chronic pancreatitis, 80% (4/5) of those who received alcohol injections reported pain relief versus 38% (5/13) of those who received steroid injections. Later, Ascunce et al. 18 conducted a retrospective multivariate analysis to determine
Figure 4 Endoscopic ultrasound (EUS)-guided direct celiac ganglia neurolysis (EUS-CGN) (EUS image). The tip of a needle is advanced deeply within a ganglion (arrow).
Thereafter, absolute ethanol is injected continuously as the needle is slowly withdrawn. After the injection, the ganglion becomes hyperechoic and difficult to visualize. Ao, aorta.
the predictive factors of response in their study in which EUS-CGN was carried out when the CG were visible by EUS and bilateral EUS-CPN was carried out otherwise. Visibility of the CG (EUS-CGN) was the best predictor of response, with patients with visible CG being 15-fold more likely to respond to the treatment (odds ratio 15.7; P = 0.001). Furthermore, in a multicenter, prospective randomized trial by Doi et al., 17 the positive response rate was significantly higher in the EUS-CGN group (73.5%) than in the EUS-CPN group (45.5%; P = 0.026). The complete response rate was also significantly higher in the EUS-CGN group (50.0%) than in the EUS-CPN group (18.2%; P = 0.010). Most recently, Minaga et al. 32 retrospectively analyzed data of 112 patients who underwent EUS-BPN to identify predictors of good response. In the multivariate analysis, EUS-BPN in combination with EUS-CGN was a predictor of a good response for pancreatic cancer pain.
Phenol injection
Recently, Ishiwatari et al.
14 investigated the effectiveness of the procedure with phenol used instead of alcohol. On day 7, there was no significant difference in the positive response rate between six patients with alcohol intolerance who were treated with phenol, and 16 control patients treated with alcohol (phenol 83% vs ethanol 69%, P = 0.6). Moreover, no significant difference was found in the rate of complications between the two groups, whereas burning pain and inebriation occurred only in the ethanol group. Later, the same researchers observed a positive response in eight of nine patients (89%) and a complete response rate of 44% in a study where highly viscous phenol-glycerol was used for EUS-CPN. 15 The median duration of pain relief was estimated to be 19.1 weeks, and adequate neurolytic agent distributions were achieved even by the central method. The authors concluded that the use of highly viscous phenolglycerol could provide excellent pain relief by enabling appropriate distribution of the neurolytic agent.
Predictors of good pain relief
As previously mentioned, some study results suggested that broad distribution of the injected ethanol was an important factor predicting a good response to EUS-CPN. 26, 27, 32 In addition, a recent prospective observational study by Bang et al. 33 suggested that heart rate change (increase of ≥15 b.p.m. for ≥30 s) during alcohol injection was associated with better pain relief and better components of quality of life such as nausea and/or vomiting, financial difficulties, weight loss, and satisfaction with body image.
Timing of procedure
Wyse et al. 13 compared pain reduction and narcotic use after early (at the time of EUS) EUS-CPN with those of conventional pain management. They concluded that early EUS-CPN can reduce pain and moderate morphine consumption in patients with painful, inoperable pancreatic cancers.
Impact of CPN on survival in patients with pancreatic cancer
Most recently, Fujii-Lau et al. 34 compared clinical and survival data of 417 patients who underwent CPN (including percutaneous CPN, EUS-CPN, and EUS-CGN) with those of 840 controls with pancreatic cancer. The median survival time of patients after CPN was shorter than that of controls (193 vs 246 days; hazard ratio = 1.32; 95% CI = 1.13-1.54). EUS-CPN was associated with longer survival than non-EUS approaches, and those who received CPN survived longer than those after CGN. However, further studies, especially prospective RCT, are needed to determine whether the shorter survival was a direct consequence of CPN or other factors such as performance status and tumor-related characteristics.
COMPLICATIONS
C OMMON REPORTED COMPLICATIONS of EUS-CPN include transient diarrhea (up to 23.4%), transient pain exacerbation (up to 36%), transient hypotension (up to 33%), and inebriation (up to 12.5%). 3, 4, 8, A recent review of 20 reports comprising 1142 patients showed that complications occurred in 7% of 481 EUS-CPB procedures and in 21% of 661 EUS-CPN procedures. 35 Most frequent complications were related to the blockade of sympathetic efferent activity (7% of patients experienced transient diarrhea, which spontaneously resolved, and hypotension was observed in 4% of patients). Transient increase of pain occurred in 2% of EUS-CPB and in 4% of EUS-CPN cases. Whether direct injection in the ganglia induces more pain or whether the immediate pain during the procedure is associated with a longerlasting relief of pain remains controversial. 35 Inebriation was reported only in Japan. 14, 17, 22, 27 In most cases, these complications are not serious. However, several major adverse events have been reported (Table 1) . 24, 25, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Most of them, especially infectious complications, were reported in patients with chronic pancreatitis. Therefore, antibiotic prophylaxis is recommended before EUS-CPB Digestive Endoscopy 2017; 29: 455-462
Celiac plexus neurolysis 459 when steroids are used. 5 Retroperitoneal bleeding occurred in two patients treated using the bilateral technique. 24, 36 Ischemic complications were lethal in three cases. 41, 44, 45 These vascular injuries and ischemic complications were probably as a result of injecting alcohol into an inappropriate site or an excessive number of sessions of EUS-CPN. Three cases of paraplegia have also been reported. 42, 43, 46 It occurred after bilateral EUS-CPN or EUS-CGN, with no cases after central EUS-CPN. The postulated mechanism of spinal cord injury in these cases involved spasm of radicular arteries because of propagation of alcohol. 35 In an RCT of EUS-CPN and -CGN, 17 the overall complication rates were similar in the two groups, but the total volume of injected ethanol was significantly lower in the EUS-CGN group (12.1 AE 5.1 mL vs 18.4 AE 3.0 mL; P < 0.001). In addition, the puncture target was clearer in EUS-CGN than in EUS-CPN. This reduction in the injection volume and better target visibility may help avoid serious ischemic complications. Paraplegia (1) PC Bilateral Lidocaine 3 mL + alcohol 9 mL + contrast agent 1 mL † Metastatic pancreatic cancer from lung cancer. ‡ Censored case. CP, chronic pancreatitis; EUS-CGN, EUS-guided direct celiac ganglia neurolysis; EUS-CPB, EUS-guided celiac plexus block; EUS-CPN, endoscopic ultrasound-guided celiac plexus neurolysis; ND, not described; PC, pancreatic cancer.
CONCLUSIONS
